1. Pink Sheet
  2. >>Market Access

Pfizer Finally Wins English Funding For Sickle Cell Drug Oxbryta After Bumpy Ride

 
• By Neena Brizmohun

After several rejections by NICE and an appeal by Pfizer, the company has reduced the price for its first-in-class sickle cell disease drug to a level that the health technology assessment institute deems acceptable.

3d rendered medical illustration of a sickle cell
Oxbryta will be funded immediately via England’s Innovative Medicines Fund. • Source: Shutterstock

Pfizer has finally secured funding for Oxbryta (voxelotor) in England after dropping its asking price for the sickle cell disease (SCD) drug, which was rejected three times by the health technology assessment institute, NICE, and subject to a successful appeal by the company.

NICE said Pfizer reduced the price to a level that reflected “the uncertainty in the evidence” that its appraisal

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Life After Loper: Vaping Case Shows US FDA Retains Considerable Deference

 
• By Craig Bleifer, Royce DuBiner, Max Bogost, Michael Brody, and Allyson Maur

A US Supreme Court ruling in favor of the agency in an e-cigarette case has implications for drugs and other medical products as the justices decided not to disturb the FDA’s ‘change in position’ authority, while also creating a complex new landscape.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

 
• By Neena Brizmohun

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.